Jaguar Health (JAGX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.53, -23.20% vs the prior close of $4.59.
- Volume 865.12K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
JAGX slides 23.2% to $3.53. Closed at $3.53, -23.20% vs the prior close of $4.59. Day range $3.25–$4.20, opened at $3.32.
JAGX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — JAGX slides 23.2% to $3.53
- Closed at $3.53, -23.20% vs the prior close of $4.59. Day range $3.25–$4.20, opened at $3.32.
- Volume was 865.12K shares, 0.3x its 50-day average of 2.64M — lighter than usual.
- Price is -59.1% vs its 50-day average ($8.62) and -97.6% vs its 200-day average ($145.17).
- 52-week range $2.35–$1,207.50; today's close sits at 0% of that range, 99.7% below the 52-week high.
Oct 15, 2026 — JAGX jumps 9.8% to $4.59
- Closed at $4.59, +9.81% vs the prior close of $4.18. Day range $3.94–$4.65, opened at $3.94.
- Volume was 425.60K shares, 0.2x its 50-day average of 2.63M — lighter than usual.
- Price is -48.0% vs its 50-day average ($8.83) and -96.9% vs its 200-day average ($147.76).
- 52-week range $2.35–$1,260.00; today's close sits at 0% of that range, 99.6% below the 52-week high.
Oct 14, 2026 — JAGX rises 0.5% to $4.18
- Closed at $4.18, +0.48% vs the prior close of $4.16. Day range $3.73–$4.35, opened at $3.84.
- Volume was 1.26M shares, 0.5x its 50-day average of 2.61M — lighter than usual.
- Price is -53.9% vs its 50-day average ($9.06) and -97.2% vs its 200-day average ($150.44).
- 52-week range $2.35–$1,260.00; today's close sits at 0% of that range, 99.7% below the 52-week high.
Oct 13, 2026 — JAGX slides 10.3% to $4.16
- Closed at $4.16, -10.34% vs the prior close of $4.64. Day range $4.07–$4.41, opened at $4.35.
- Volume was 434.70K shares, 0.2x its 50-day average of 2.60M — lighter than usual.
- Price is -55.2% vs its 50-day average ($9.28) and -97.3% vs its 200-day average ($153.28).
- 52-week range $2.35–$1,260.00; today's close sits at 0% of that range, 99.7% below the 52-week high.
Oct 12, 2026 — JAGX slides 3.1% to $4.64
- Closed at $4.64, -3.13% vs the prior close of $4.79. Day range $4.32–$4.83, opened at $4.83.
- Volume was 481.30K shares, 0.2x its 50-day average of 2.59M — lighter than usual.
- Price is -51.1% vs its 50-day average ($9.49) and -97.0% vs its 200-day average ($156.22).
- 52-week range $2.35–$1,260.00; today's close sits at 0% of that range, 99.6% below the 52-week high.
Oct 9, 2026 — JAGX jumps 5.7% to $4.79
- Closed at $4.79, +5.74% vs the prior close of $4.53. Day range $4.47–$5.33, opened at $4.56.
- Volume was 1.09M shares, 0.4x its 50-day average of 2.57M — lighter than usual.
- Price is -50.6% vs its 50-day average ($9.70) and -97.0% vs its 200-day average ($159.06).
- 52-week range $2.35–$1,267.88; today's close sits at 0% of that range, 99.6% below the 52-week high.
Oct 8, 2026 — JAGX slides 9.4% to $4.53
- Closed at $4.53, -9.40% vs the prior close of $5.00. Day range $4.36–$4.94, opened at $4.82.
- Volume was 590.30K shares, 0.2x its 50-day average of 2.55M — lighter than usual.
- Price is -54.3% vs its 50-day average ($9.92) and -97.2% vs its 200-day average ($162.16).
- 52-week range $2.35–$1,267.88; today's close sits at 0% of that range, 99.6% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 7, 2026 — JAGX slides 11.0% to $5.00
- Closed at $5.00, -11.03% vs the prior close of $5.62. Day range $4.91–$5.50, opened at $5.24.
- Volume was 1.21M shares, 0.5x its 50-day average of 2.53M — lighter than usual.
- Price is -50.6% vs its 50-day average ($10.11) and -97.0% vs its 200-day average ($165.21).
- 52-week range $2.35–$1,267.88; today's close sits at 0% of that range, 99.6% below the 52-week high.
Oct 6, 2026 — JAGX jumps 18.8% to $5.62 on 13.6x normal volume
- Closed at $5.62, +18.82% vs the prior close of $4.73. Day range $5.34–$7.27, opened at $6.56.
- Volume was 27.07M shares, 13.6x its 50-day average of 1.99M — unusually heavy trading.
- Price is -45.5% vs its 50-day average ($10.30) and -96.7% vs its 200-day average ($168.15).
- 52-week range $2.35–$1,267.88; today's close sits at 0% of that range, 99.6% below the 52-week high.
Oct 5, 2026 — JAGX jumps 29.2% to $4.73 on 14.1x normal volume
- Closed at $4.73, +29.23% vs the prior close of $3.66. Day range $4.10–$6.00, opened at $4.27.
- Volume was 21.90M shares, 14.1x its 50-day average of 1.55M — unusually heavy trading.
- Price is -54.9% vs its 50-day average ($10.49) and -97.2% vs its 200-day average ($171.25).
- 52-week range $2.35–$1,267.88; today's close sits at 0% of that range, 99.6% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — JAGX slides 7.3% to $3.66, 5 down days in a row
- Closed at $3.66, -7.34% vs the prior close of $3.95. Day range $3.50–$4.30, opened at $4.15.
- Volume was 591.50K shares, 0.4x its 50-day average of 1.54M — lighter than usual.
- Price is -65.7% vs its 50-day average ($10.69) and -97.9% vs its 200-day average ($174.48).
- 52-week range $2.35–$1,267.88; today's close sits at 0% of that range, 99.7% below the 52-week high.
- That makes 5 straight losses.
JAGX latest news & SEC filings
Every SEC filing by or about JAGX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 29, 2026 · Form PRER14A — PRER14A filing
PRER14A filing
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Sep 24, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 24, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 3, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 21, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade JAGX
- Last results release: Aug 19, 2026 (8-K Item 2.02). Previous ones: May 20, 2026, Apr 7, 2026, May 15, 2025. Based on that rhythm, the next report is likely around Nov 18, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 74.28% (largest 1190.6%). That is a volatile stock.
- Liquidity: about 6.56M shares (≈$23.14M) trade per day on average.
- 52-week position: $3.53 vs a range of $2.35–$1,207.50 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:15 on Sep 17, 2026, 1:35 on Apr 30, 2026, 1:25 on Mar 24, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 5, 2026; 8-K Sep 28, 2026; 8-K Sep 25, 2026.
- Share count: 171.35M shares outstanding (May 15, 2018), +1086.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
JAGX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.32 | 4.20 | 3.25 | 3.53 | 865.12K |
| Oct 15, 2026 | 3.94 | 4.65 | 3.94 | 4.59 | 438.90K |
| Oct 14, 2026 | 3.84 | 4.35 | 3.73 | 4.18 | 1.26M |
| Oct 13, 2026 | 4.35 | 4.41 | 4.07 | 4.16 | 434.70K |
| Oct 12, 2026 | 4.83 | 4.83 | 4.32 | 4.64 | 481.30K |
| Oct 9, 2026 | 4.56 | 5.33 | 4.47 | 4.79 | 1.09M |
| Oct 8, 2026 | 4.82 | 4.94 | 4.36 | 4.53 | 590.30K |
| Oct 7, 2026 | 5.24 | 5.50 | 4.91 | 5.00 | 1.21M |
| Oct 6, 2026 | 6.56 | 7.27 | 5.34 | 5.62 | 27.07M |
| Oct 5, 2026 | 4.27 | 6.00 | 4.10 | 4.73 | 21.90M |
| Oct 2, 2026 | 4.15 | 4.30 | 3.50 | 3.66 | 591.50K |
| Oct 1, 2026 | 4.34 | 4.48 | 3.82 | 3.95 | 463.60K |
| Sep 30, 2026 | 5.04 | 5.14 | 4.41 | 4.50 | 732.30K |
| Sep 29, 2026 | 5.37 | 6.10 | 5.00 | 5.32 | 943.90K |
| Sep 28, 2026 | 6.99 | 7.25 | 5.80 | 6.02 | 1.41M |
| Sep 25, 2026 | 9.09 | 12.10 | 6.80 | 7.70 | 30.02M |
| Sep 24, 2026 | 7.03 | 7.72 | 6.02 | 7.06 | 2.08M |
| Sep 23, 2026 | 15.43 | 19.46 | 8.50 | 8.91 | 11.66M |
| Sep 22, 2026 | 2.83 | 41.53 | 2.75 | 34.46 | 27.95M |
| Sep 21, 2026 | 2.87 | 2.87 | 2.48 | 2.67 | 72.90K |
About Jaguar Health
Jaguar Health (JAGX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1585608.
JAGX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James J Bochnowski | Director | Dec 15, 2025 |
| Lisa A Conte | See Remarks | Jan 21, 2026 |
| Anula Jayasuriya | Director | Dec 15, 2025 |
| John Micek | Director | Mar 12, 2026 |
| Jonathan B. Siegel | Director | Dec 15, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Lisa A Conte | See Remarks | Jan 21, 2026 |
| Pravin R Chaturvedi | Chief Scientific Officer | Dec 15, 2025 |
| Steven R. King | See Remarks | Jan 21, 2026 |
| Carol R. Lizak | Chief Financial Officer | Dec 15, 2025 |
| Jonathan S. Wolin | See Remarks | Jan 21, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
JAGX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $11.51M | $-53.58M | -22.97 | $-23.69M |
| Dec 31, 2024 | $11.69M | $-38.49M | -130.69 | $-29.38M |
| Dec 31, 2023 | $9.76M | $-41.30M | -2,678.17 | $-33.24M |
| Dec 31, 2022 | $11.96M | $-47.45M | -36.18 | $-33.10M |
| Dec 31, 2021 | $4.33M | — | -88.22 | $-34.97M |
Latest balance sheet: total assets $34.19M, total liabilities $29.27M, cash $3.79M (as of Jun 30, 2026).
JAGX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 19, 2026 | 8-K Item 2.02 (results) | $13.86 |
| May 20, 2026 | 8-K Item 2.02 (results) | $55.05 |
| Apr 7, 2026 | 8-K Item 2.02 (results) | $215.25 |
| May 15, 2025 | 8-K Item 2.02 (results) | $2,887.50 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $2,499.00 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $12,967.50 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| Aug 14, 2023 | 8-K Item 2.02 (results) | — |
| May 15, 2023 | 8-K Item 2.02 (results) | — |
| Mar 27, 2023 | 8-K Item 2.02 (results) | — |
| Nov 14, 2022 | 8-K Item 2.02 (results) | — |
| May 10, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on JAGX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.